Key Findings
The ‘China Plus One’ strategy in the Asia Pacific (APAC) region is creating new opportunities for Japan’s biopharmaceutical Contract Development and Manufacturing Organization (CDMO) industry, driven by geopolitical risk diversification and supply chain resilience objectives. Leading CDMOs, including FUJIFILM Diosynth Biotechnologies, are making significant investments, with FUJIFILM Diosynth allocating over $4 billion to global expansion. Under its economic security legislation, the Japanese government is channeling subsidies into building domestic CDMO manufacturing capabilities that prioritize quality, explicitly differentiating Japan’s strategy from quantity-driven outsourcing.
Technical and Clinical Details
The ‘China Plus One’ strategy aims to enhance supply chain stability and resilience by diversifying manufacturing bases outside of China. In the APAC region, Japan, South Korea, Singapore, and India are strong contenders. FUJIFILM Diosynth Biotechnologies is expanding its manufacturing capabilities for cell and gene therapy products and biopharmaceuticals globally, with total investments exceeding $4 billion. This move is a strategic response to increasing global biopharmaceutical demand and the need to bolster capacity for emerging modalities. AGC Biologics is also advancing facility expansions in Japan and Seattle, enhancing its cell culture and process development capabilities. In Japan, government subsidy programs specifically target the development of CDMOs with advanced manufacturing technologies, stringent quality control systems, and robust regulatory compliance capabilities. This initiative aims to leverage Japan’s high technological standards and quality management expertise for the production of complex, high-value biopharmaceuticals, particularly cell and gene therapy products.
Background and Industry Context
In recent years, vulnerabilities in global supply chains have become evident, making the secure supply of pharmaceuticals a priority for national governments worldwide. Biopharmaceuticals, especially, require complex manufacturing processes and highly specialized expertise, leading to a strong reliance on trustworthy CDMOs. Against this backdrop, the ‘China Plus One’ strategy has become a critical consideration for pharmaceutical companies, particularly in Western countries, when selecting manufacturing partners. Japan, with its stringent quality control culture, advanced technological infrastructure, and strong government support, is establishing itself as a high-quality biomanufacturing hub. This makes it an attractive option for clients who prioritize quality and reliability over purely quantitative cost competition.
Strategic Significance and Outlook
Japan’s CDMO industry is expected to further strengthen its quality-focused strategy through sustained government support and global partnerships. This will enable Japan to solidify its presence as a manufacturing hub for cell and gene therapies and other high-value biopharmaceuticals in the Asian region. Increased competition among CDMOs in the region will also drive further innovation and efficiency in manufacturing technologies, ultimately contributing to the stable supply of high-quality medicines to patients. The integration of AI, data science, and automation technologies will be key for Japanese CDMOs to maintain their competitiveness in the global market.
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments